Phase 3 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old (inclusive)
- You have been diagnosed with primary Sjögren's Syndrome according to recognised international guidelines (from 2016)
- Your Sjögren's Syndrome is considered active enough to meet a minimum disease activity score of 5 on a specific measurement tool called the ESSDAI (confirm with trial site)
- A blood test shows you carry specific antibodies linked to Sjögren's Syndrome, known as SSA/Ro antibodies
Who may not be able to join:
- You have another systemic autoimmune disease (such as rheumatoid arthritis, lupus, or systemic sclerosis) that better explains most of your symptoms, meaning your Sjögren's is considered secondary rather than primary
- You have another autoimmune or inflammatory condition (such as inflammatory bowel disease or gout) that could make it difficult to measure how well your Sjögren's responds to treatment
- You have severe fibromyalgia (a chronic pain condition) that could interfere with measuring how your Sjögren's Syndrome responds to treatment
- Your Sjögren's Syndrome is causing serious, life-threatening complications to your organs at the time of screening, as judged by the study doctor
- You have a significant, poorly controlled medical condition in any part of your body unrelated to Sjögren's Syndrome (such as poorly controlled asthma, heart disease, high blood pressure, or major depression) that the study doctor feels would make participation unsafe
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 6176556580
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.